Toronto, ON, Canada (PRWEB) November 28, 2013
Women in several other parts of the world will soon have access to femMED products, a Canadian-based line of natural women’s health supplements for a wide variety of important health concerns from breast and bone health to symptoms of menopause and premenstrual syndrome, among others. The news comes as parent company Fem Med Formulas enters into an agreement with NewBridge Pharmaceuticals, a specialty therapeutics company commercializing pharmaceuticals, biologics, diagnostics and medical devices across the AfMET region.
The exclusive license and supply agreement will expand femMED’s market to include countries of the Middle East, Turkey and Caspian Regions. NewBridge will manage all aspects of the local regulatory approval process, as well as product sales, marketing and distribution.
The agreement gives NewBridge Pharmaceuticals licensing rights to all 13 doctor-formulated femMED supplements designed to address the unique health needs of women, including its flagship Breast Health formula which underwent a Health Canada approved, double-blind, placebo-controlled human clinical trial resulting in a proven mechanism to promote a healthy estrogen metabolite ratio. The study was published in the PubMed Index Journal, Breast Cancer: Basic & Clinical Research, as well as the Natural Medicine Journal. The other products in the femMED line are diverse, and designed to address symptoms of menopause, perimenopause and Premenstrual Syndrome (PMS); support the maintenance of healthy bones, heart and weight; aid with sleep disturbances, declines in energy and libido levels; and improve the appearance of hair, skin and nails. The brand also includes a superior multi plus antioxidants formula and two prenatal supplements providing premium supplementation and management of nausea for mothers-to-be.
“We work hard to provide women with best-in-class supplements for their most common health concerns, and are excited to partner with NewBridge Pharmaceuticals to broaden our reach and provide our doctor-formulated supplements to women living in countries of the AfMET region.” said Shawna Page, founder and CEO of femMED. “Helping women live a healthy and balanced life is core to femMED. Being issued NPNs from Health Canada for all 13 of our formulations is assurance that our rigorous testing and commitment to women’s health, results in effective natural health products.”
“We are delighted to partner with femMED Formulas to launch a novel line of quality all-natural supplements to physicians and patients in the AfMET region”, said Joe Henein, President and CEO of NewBridge Pharmaceuticals. “This partnership represents an important addition to our growing product portfolio of therapeutics addressing disease areas for women. Introducing femMED, which consists of 13 doctor-formulated supplements will complement the unmet health needs and improve the overall well-being of women in our region.”
Media Note: For additional information, or to schedule an interview, contact Media Relations, Inc. at 952-697-5220.
Founded in 2007, femMED is a brand of comprehensive supplements designed specifically for the unique needs of women. femMED’s line of 13 doctor-formulated remedies provide natural solutions to women’s most common health concerns, at every age and stage of life. Each product contains only the highest quality vitamins, minerals and herbs, with each ingredient backed by extensive research and clinical studies. All femMED formulations are free of gluten, dairy, egg, artificial colours and flavours, and almost all are yeast-free, suitable for vegetarians and delivered in vegetable capsules. femMED formulas are designed to work on their own, or in combination with other femMED formulas to achieve multiple health goals. All products are produced in Canadian pharmaceutically licensed facilities. For more information about femMED supplements, please visit http://www.femmed.com
About NewBridge Pharmaceuticals
NewBridge Pharmaceuticals is a first-in-class specialty therapeutics company focused on pharmaceuticals, biologics, medical diagnostics and other innovative healthcare products serving the AfMET markets (Africa, Middle East and Turkey) to address the unmet medical needs of diseases with high regional prevalence. Headquartered in the UAE with strong local and international business network, NewBridge is uniquely positioned as the partner-of-choice for pharmaceutical, biotechnology and other healthcare companies seeking to create value for their pharma or medical products in the high growth emerging AfMET markets. For more information, please visit http://www.nbpharma.com.